Cwm LLC Has $87.91 Million Position in AbbVie Inc. $ABBV

Cwm LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 17.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 379,652 shares of the company’s stock after acquiring an additional 56,269 shares during the quarter. Cwm LLC’s holdings in AbbVie were worth $87,905,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. TD Capital Management LLC boosted its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. bought a new position in AbbVie in the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC acquired a new position in AbbVie during the 2nd quarter valued at $28,000. Finally, Financial Gravity Companies Inc. acquired a new stake in AbbVie in the 2nd quarter worth $36,000. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of ABBV stock opened at $230.18 on Friday. The stock has a 50-day moving average of $226.72 and a 200-day moving average of $212.12. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market cap of $406.81 billion, a PE ratio of 174.38, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s payout ratio is presently 496.97%.

Analyst Ratings Changes

Several research firms have commented on ABBV. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Morgan Stanley lifted their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Bank of America lifted their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Evercore ISI raised their price target on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Finally, JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.